Geographic Atrophy Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Apellis Pharmaceuticals, Iveric Bio (Zimura), NGM Biopharmaceuticals (NGM621), Ionis Pharmaceuticals

Globally, about 23+ key pharma and biotech companies are working on 25+ pipeline drugs in the Geographic Atrophy therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Geographic Atrophy Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Geographic Atrophy Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Geographic Atrophy Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Geographic Atrophy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Geographic Atrophy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

DelveInsight's Report covers around 25+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Geographic Atrophy Therapeutics Analysis
There are approx. 23+ key companies developing therapies for Geographic Atrophy. Currently, IVERIC bio has its Geographic Atrophy drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Geographic Atrophy Therapeutics Market include:
Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc, Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others

Geographic Atrophy Therapies covered in the report include:
IONIS-FB-LRx: Ionis Pharmaceuticals
Zimura: IVERIC bio
And many more

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Geographic Atrophy Current Treatment Patterns
4. Geographic Atrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Geographic Atrophy Late Stage Products (Phase-III)
7. Geographic Atrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Geographic Atrophy Discontinued Products
13. Geographic Atrophy Product Profiles
14. Geographic Atrophy Key Companies
15. Geographic Atrophy Key Products
16. Dormant and Discontinued Products
17. Geographic Atrophy Unmet Needs
18. Geographic Atrophy Future Perspectives
19. Geographic Atrophy Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.